Jefferies initiates Abivax stock coverage with buy rating on UC drug

🇫🇷 Investing.com (FR) —
Jefferies initiates Abivax stock coverage with buy rating on UC drug

AI Summary

Jefferies has initiated coverage of Abivax stock with a buy rating, expressing optimism about the company's ulcerative colitis (UC) drug candidate. The initiation signals analyst confidence in Abivax's pipeline and commercial prospects.

Markets Health Abivax Jefferies buy rating ulcerative colitis biotech analyst coverage

Read original source →